Keytruda might be prescribed by itself or with lenvatinib (Lenvima) in this case. TNBC with PD-L1 that’s recurring but can’t be removed by surgery, or is spreading from the breast to other ...

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

Merck is planning to look at the combination of Lenvima and Keytruda in previously-untreated patients, while Roche recently picked up an FDA breakthrough designation for its PD-L1 inhibitor ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.

In oncology drugs, Keytruda sales are likely to have been ... Alliance revenues from Lenvima may have also boosted oncology sales. Sales of Welireg are likely to have been driven by the launch ...